NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 726-730

  Peres da Silva, Allan ^a   De Almeida, Adilson José ^a,b   Lampe, Elisabeth ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b HOSPITAL UNIVERSITÁRIO GAFFRÉE E GUINLE   (Brazil)

Author keywords

DAAs; HCV; NS5A gene

Indexed keywords

ACH 3102; AMINO ACID; DACLATASVIR; GSK 2336805; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; RAVIDASVIR; SAMATASVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BRAZILIAN; CLADISTICS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PHYLOGENETIC TREE; VIRUS MUTATION; BRAZIL; CLINICAL TRIAL (TOPIC); CLUSTER ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR GENETICS; PHYLOGENY; SERUM; VIROLOGY;

ANTIVIRAL AGENTS; BRAZIL; CLINICAL TRIALS AS TOPIC; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; SERUM; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84928175672     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku462     Document Type: Article

References (20)

1. Pereira LM, Martelli CM, Moreira RC et al. Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 2013; 13: 60.
2. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013; 22:1107-21.
3. Fontana RJ, Hughes EA, Appelman H et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-9.
4. Suzuki Y, Ikeda K, Suzuki F et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-62.
5. Gao M, Nettles RE, Belema M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
6. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013; 3: 514-20.
7. Fridell RA, Wang C, Sun JH et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-35.
8. Walker J, Crosby R, Wang A et al. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother 2014; 58: 38-47.
9. Peres-da-Silva A, Almeida AJ, Lampe E. Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs. Mem Inst Oswaldo Cruz 2012; 107: 254-61.
10. Soriano V, Vispo E, Poveda E et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011; 66: 1673-86.
11. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59: 375-82.
12. Fridell RA, Qiu D, Wang C et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54: 3641-50.
13. Murakami E, Imamura M, Hayes CN et al. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother 2014; 58: 2105-12.
14. Jardim AC, Bittar C, Matos RP et al. Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infect Dis 2013; 13: 61.
15. Pickett BE, Striker R, Lefkowitz EJ. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 2011; 18: 608-18.
16. Korber B, Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 1992; 8: 1549-60.
17. Plaza Z, Soriano V, Vispo E et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 2012; 17: 921-6.
18. Suzuki F, Sezaki H, Akuta N et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54: 352-4.
19. Sun JH, O'Boyle Ii DR, Zhang Y et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012; 55: 1692-9.
20. De Luca A, Di Giambenedetto S, ProsperiMet al. Two distinct HCVgenotype 1a clades: geographical distribution and association with natural resistance mutations to HCVNS3/4A inhibitors. Antiviral Ther 2013; 18:Suppl 1: A47.